Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 8, 2021.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Mike Hennessy Sr, Founder and Chairman, MJH Life Sciences, penned an op-ed praising the efforts of the medical and pharmaceutical communities for their swift action in developing vaccines in record time for COVID-19.
The executive director of the Norman Fixel Institute for Neurological Diseases explained how disease-based registries play a crucial part in changing the approval system for neurologic devices in rare diseases.
A discussion with Amaal Starling, MD, on the significance of the approval of a 5-HT1F agonist, with special consideration of the safety and efficacy from the respective clinical trial.
A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.
M. Scott Perry, MD, reviews how cannabidiol and fenfluramine are chosen for patients with Dravet syndrome based on concomitant medications and associated adverse events.